GammaCan Signs $6.5 Million Private Placement with Institutional Investors

  
    
  
  
    
      GammaCan International, Inc. (“GammaCan” 
      or "the Company”) (OTCBB: GCAN), a 
      developer of novel immunotherapies to treat cancer, announced today the 
      completion of a $6.5 million private placement with a group of investors 
      lead by T.R. Winston & Company, LLC. The Company issued 16,250,000 
      common shares at a price of $0.40 per share, and warrants equal to the 
      amount of shares issued, exercisable at $0.48. Details of the 
      transaction will be described in a Form 8-K to be filed with the 
      Securities and Exchange Commission.
    
    
      “We are most pleased with the confidence and 
      support shown in the Company by our new and existing investors,” 
      stated Steven Katz, Chairman of the Board. “These 
      funds will enable us to continue the development of VitiGam™ 
      for the treatment of Stage III and Stage IV melanoma,” 
      said Patrick Schnegelsberg, CEO. “T.R. Winston 
      is a solid partner and we are looking forward to a valuable long-term 
      relationship,” added Schnegelsberg.
    
    
      About GammaCan
    
    
      GammaCan develops innovative immunotherapy and related approaches to 
      treat cancer. GammaCan's platform technology is based on IgGs, a safe, 
      relatively non-toxic human plasma-based product used to treat a variety 
      of immune deficiencies and autoimmune diseases. In cancer, IgG-based 
      therapies work by strengthening the patient's immune system. Many 
      experts currently view immunotherapy as a future alternative to 
      chemotherapy. For more information about GammaCan, visit www.GammaCan.com.
    
    
      About VitiGam™
    
    
      VitiGam™ is a first-in-class IgG-based 
      anti-cancer immunotherapy being developed for the treatment of Stage III 
      and Stage IV melanoma. GammaCan is planning to submit its 
      Investigational New Drug Application (IND) for VitiGam™ 
      to the FDA in the near future. The Company is expecting to commence 
      human clinical trials shortly thereafter. VitiGam™ 
      is an IgG-based product manufactured from the plasma of donors with 
      Vitiligo, a benign skin condition affecting up to 2% of the general 
      population. Studies have shown that this "enriched" IgG formulation 
      contains potent anti-melanoma activity. Based on these studies, GammaCan 
      expects VitiGam™ to provide both, specific 
      anti-melanoma activity (directed against melanoma cells), and 
      non-specific anti-cancer activity.
    
    
      Safe Harbor Statement:
    
    
      Statements in this document that are not purely historical are 
      forward-looking statements. Forward-looking statements in this release 
      include statements regarding: the commercialization of anti-cancer 
      immunotherapies and the Company’s efforts to 
      develop therapies to boost the immune systems of cancer patients by the 
      use of IgG-based therapy. Actual outcomes and the Company's actual 
      results could differ materially from those in such forward-looking 
      statements. Factors that could cause actual results to differ materially 
      include risks and uncertainties such as the inability to finance the 
      planned development of the technology, the inability to hire appropriate 
      staff to develop the technology, unforeseen technical difficulties in 
      developing the technology, the inability to obtain regulatory approval 
      for human use, competitors' therapies proving to be more effective, 
      cheaper or otherwise preferable for consumers, the inability to market 
      the product we produce, all of which could, among other things, delay or 
      prevent product release, as well as other factors expressed from time to 
      time in GammaCan’s periodic filings with the 
      Securities and Exchange Commission (the "SEC"). As a result, this press 
      release should be read in conjunction with GammaCan's periodic filings 
      with the SEC, which are incorporated herein by reference. The 
      forward-looking statements contained herein are made only as of the date 
      of this press release, and GammaCan undertakes no obligation to publicly 
      update such forward-looking statements to reflect subsequent events or 
      circumstances.